Small non‐coding RNA and colorectal cancer

Chen, Hui; Xu, Zu-De; Liu, Deliang

doi:10.1111/jcmm.14209

Cited by 74 publications

(36 citation statements)

References 114 publications

(171 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous study have confirmed that miRNAs play key role in the progression of BCa 18 . The multiple effects exerted by miRNAs in BCa cells include the regulation of proliferative, apoptotic, autophagic, migratory, invasive, metastatic, epithelial-mesenchymal transition (EMT), angiogenic and drug resistant phenotypes 19 . Dysregulated miR-96-5p expression occurs in numerous cancers.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-96-5p represses breast cancer proliferation and invasion through Wnt/β-catenin signaling via targeting CTNND1

Gao

Zhang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Low miR-96-5p expression is characteristic of many cancers but its role in breast cancer (BCa) remains poorly defined. Here, the role of miR-96-5p in BC development was assessed. We demonstrate that exogenously expressing miR-96-5p inhibits the proliferative, migratory and invasive capacity of BCa cells. Mechanistically, miR-96-5p in BCa cells was found to target and downregulate catenin delta 1 (CTNND1) leading to decreased β-catenin expression, a loss of WNT11 signaling, reduced cyclin D1 levels and lower MMP7 expression. Exogenously expressing CTNND1 alleviated these effects. In summary, we are the first to reveal that miR-96-5p inhibits the proliferative, invasive and migratory phenotypes of BCa cells the targeting of CTNND1 and subsequent Wnt/β-catenin signaling. These data highlight miR-96-5p as a novel target for BC treatment. Of all life-threatening human cancer cases, breast cancer (BCa) remains the most commonly diagnosed 1. In the United States (US), nearly 330,000 new cases of BC occurred in 2017 over a third of which were invasive 2. Despite great strides to improve BCa diagnostics and therapeutics, the rates of mortality remain high with over 40000 deaths occurring in 2017 in the US alone 2. BCa cells possess a remarkable ability to metastasize to the bone marrow, the regional lymph nodes, liver, and the lungs forming a distinct tissue microenvironment (TME) that permits efficient dissemination from the site of the primary tumor 3,4. Identifying the molecular mechanisms controlling BCa progression can thus inform the design of more efficacious anti-BCa therapies. It is now well-accepted that the dysregulation of cellular MicroRNAs (miRNAs) leads to a range of pathological processes in animals and humans mediated through their ability to bind protein-coding transcripts 5. An increasing body of evidence points to the presence of a link between miRNAs to the initiation, development, and metastasis of various types of tumors, including BC 6-9. Although miR-96-5p is implicated in multiple cancers 10-12 , little is known regarding its relationship to the development and progression of BC. Here, we assessed the contribution of miR-96-5p to BCa and reveal its downregulation in BCa cells. We demonstrate that exogenously increasing miRNA-95-5p expression inhibits the proliferative and metastatic potential of BCa cells which is in part, mediated through the targeting of catenin delta 1 (CTNND1) and subsequent Wnt/β-catenin signaling. We thus highlight miR-96-5p as a novel therapeutic for much needed anti-BCa treatments. Methods Tissues and cells. We collected 155 BCa samples and non-tumor tissues. Included patients received no prior chemotherapy, immunotherapy, or radiotherapy prior to the surgery. Samples were verified as BCa for an experienced pathologist and frozen in liquid N2 prior to use. All patients signed an informed consent form. The protocol of the study was reviewed and approved by the Institutional Human Experiment and Ethic Committee of the First Affiliated Hospital of Henan University of Science...

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-96-5p represses breast cancer proliferation and invasion through Wnt/β-catenin signaling via targeting CTNND1

Gao

Zhang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Therefore, tRF/miR1280 suppressed colorectal cancer progression by repressing the Notch signaling that was important to CSCs. 73,74 Soares et al have examined the presence of tRFs, including 5 0 tRF-Lys TTT , 5 0 tRF-Val CAC , 5 0 tRF-Glu CTC and 5 0 tRF-Pro CGG that the 5 0 tRF-Val CAC level was slightly decreased in cancer cells, while it was significantly downregulated after transcatheter arterial infusion chemotherapy. 5 0 tRF-Glu CTC was decreased independently of transcatheter arterial infusion chemotherapy.…”

Section: Colorectal Cancermentioning

confidence: 99%

Relationship between tRNA‐derived fragments and human cancers

Zeng

Hua

Sun

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

tRNA-derived fragments, a class of small noncoding RNAs (sncRNAs), have been identified in numerous studies in recent years. tRNA-derived fragments are classified into two main groups, including tRNA halves (tiRNAs) and tRNA-derived small RNA fragments (tRFs), according to different cleavage positions of the precursor or mature tRNAs. Instead of random tRNA degradation debris, a growing body of evidence has shown that tRNA-derived fragments are precise products of specific tRNA modifications and play important roles in biological activities, such as regulating protein translation, affecting gene expression, and altering immune signaling. Recently, the relations between tRNA-derived fragments and the occurrence of human diseases, especially cancers, have generated wide interest. It has been demonstrated that tRNA-derived fragments are involved in cancer cell proliferation, metastasis, progression and survival. In this review, we will describe the biogenesis of tRNA-derived fragments, the distinct expression and function of tRNA-derived fragments in the development of cancers, and their emerging roles as diagnostic and prognostic biomarkers and precise targets of future treatments.

show abstract

“…TRF-3 (13-22Nucleotide[nt]) can be further classified into tRF-3 and tRF-3b, while t-RF-5 can be classified into three subtypes: tRF-5a (14-16nt), tRF-5b (22-24nt) and tRF-5c (28-30nt) (16). TiRNAs are non-coding small RNAs with 31-40 nucleotides in length, which can be classified into 3'-tiRNAs and 5'-tiRNAs (11,(17)(18)(19)(20)(21). The type of tsRNAs was shown in Figure 1.…”

Section: Classification Of Trfs and Tirnasmentioning

confidence: 99%

The role of Transfer RNA-Derived Small RNAs (tsRNAs) in Digestive System Tumors

Wang¹,

Yan²,

Xu³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Transfer RNA-derived small RNA(tsRNA) is a type of non-coding tRNA undergoing cleavage by specific nucleases such as Dicer. TsRNAs comprise of tRNA-derived fragments (tRFs) and tRNA halves (tiRNAs). Based on the splicing site within the tRNA, tRFs can be classified into tRF-1, tRF-2, tRF-3, tRF-5, and i-tRF. TiRNAs can be classified into 5′-tiRNA and 3′-tiRNA. Both tRFs and tiRNAs have important roles in carcinogenesis, especially cancer of digestive system. TRFs and tiRNAs can promote cell proliferation and cell cycle progression by regulating the expression of oncogenes, combining with RNA binding proteins such as Y-box binding protein 1 (YBX1) to prevent transcription. Despite many reviews on the basic biological function of tRFs and tiRNAs, few have described their correlation with tumors especially gastrointestinal tumor. This review focused on the relationship of tRFs and tiRNAs with the biological behavior, clinicopathological characteristics, diagnosis, treatment and prognosis of digestive system tumors, and would provide novel insights for the early detection and treatment of digestive system tumors.

show abstract

Small non‐coding RNA and colorectal cancer

Cited by 74 publications

References 114 publications

MicroRNA-96-5p represses breast cancer proliferation and invasion through Wnt/β-catenin signaling via targeting CTNND1

MicroRNA-96-5p represses breast cancer proliferation and invasion through Wnt/β-catenin signaling via targeting CTNND1

Relationship between tRNA‐derived fragments and human cancers

The role of Transfer RNA-Derived Small RNAs (tsRNAs) in Digestive System Tumors

Contact Info

Product

Resources

About